title: Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.
abstract: BACKGROUND
  Plaque reduction with the use of pioglitazone and statin combination therapy has been observed in carotid plaque. We sought to investigate the effect of combination therapy with statins and pioglitazone on coronary plaque regression and composition with the use of intravascular ultrasound (IVUS) and intravascular ultrasound-virtual histology (IVUS-VH).
  
  
  METHODS
  We analysed 29 plaques in 25 diabetic patients with angiographic evidence of nonsignificant coronary lesions with IVUS-VH. Patients were treated with 80 mg of atorvastatin and 30 mg of pioglitazone daily for 6 months. After 6 months of therapy, IVUS-VH of each lesion was reacquired.
  
  
  RESULTS
  Mean elastic external membrane volume was significantly reduced between baseline and follow-up (343.9 vs. 320.5 mm; P < 0.05) as was mean total atheroma volume (179.3 vs. 166.6 mm; P < 0.05). Change in total atheroma volume showed a 6.3% mean reduction. Areas of fibrous tissue, fibrolipidic tissue and calcium decreased over the 6 months of follow-up, although not significantly. On the other hand, the necrotic core increased from 9 to 14% (P < 0.05).
  
  
  CONCLUSIONS
  Our data demonstrated that atorvastatin/pioglitazone association is able to induce significant regression of coronary atherosclerosis, acting on plaque composition. Our findings are preliminary results and will be confirmed in an ongoing randomized placebo-controlled multicenter trial (PIPER; Pioglitazone for Prevention of Restenosis in Diabetics with Complex Lesion; trial registration: clinical trials.gov. Identifier: NCT 00376870).
authors.affiliation: Department of Cardiology, Tor Vergata University, Rome, Italy. fabrizio.clementi@me.com
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Clementi
authors.forename: Marco
authors.initials: M
authors.lastname: Di Luozzo
authors.forename: Ruggiero
authors.initials: R
authors.lastname: Mango
authors.forename: Giulio
authors.initials: G
authors.lastname: Luciani
authors.forename: Antonio
authors.initials: A
authors.lastname: Trivisonno
authors.forename: Francesco
authors.initials: F
authors.lastname: Pizzuto
authors.forename: Eugenio
authors.initials: E
authors.lastname: Martuscelli
authors.forename: Jawahar L
authors.initials: JL
authors.lastname: Mehta
authors.forename: Francesco
authors.initials: F
authors.lastname: Romeo
mesh_terms: D000368:Aged; D000069059:Atorvastatin; D002114:Calcinosis / Q000000981:diagnostic imaging / Q000188:drug therapy; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003920:Diabetes Mellitus / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005355:Fibrosis; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D010865:Pilot Projects; D000077205:Pioglitazone; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*; D012042:Registries; D045162:Thiazolidinediones / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional; D014584:User-Computer Interface
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D011758:Pyrroles; D045162:Thiazolidinediones; D000069059:Atorvastatin; D000077205:Pioglitazone